Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

DOXY 200

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

47 API Suppliers, 21 USDMF, 11 CEP/COS, 1 JDMF, 2 EU WC, 2 KDMF, 14 NDC API, 1 VMF, 21 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

47 Drugs in Development

47 Drugs in Development

FINISHED DOSAGE FORMULATIONS

239 FDF Dossiers, 188 FDA Orange Book, 11 Europe, 15 Canada, 25 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE, CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE, SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG, TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 18 SPI Pharma, 12 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 6 Kirsch Pharma, 4 ACG Worldwide, 12 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 33 BASF, 1 CD Formulation, 1 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 3 Finar, 12 Gangwal Chemicals, 6 Ideal Cures, 5 Ingredion Pharma Solutions, 27 Kerry, 4 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 22 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

85 Fillers, Diluents & Binders, 60 Coating Systems & Additives, 45 Thickeners and Stabilizers, 45 Disintegrants & Superdisintegrants, 44 Direct Compression, 38 Granulation, 32 Parenteral, 30 Solubilizers, 29 Controlled & Modified Release, 27 Film Formers & Plasticizers, 25 Taste Masking, 21 Topical, 21 Chewable & Orodispersible Aids, 21 Lubricants & Glidants, 15 Co-Processed Excipients, 11 Rheology Modifiers, 9 Emulsifying Agents, 9 Empty Capsules, 7 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 53 News #PharmaBuzz

GLOBAL SALES INFORMATION

38 US Medicaid Prescriptions, 18 Regulatory FDF Prices

MARKET PLACE

72 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents

14 US Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Hebei Dongfeng Pharmaceutical Co., Ltd	China	Hebei Dongfeng Pharmaceutical Co., Ltd Handan City CN	R1-CEP 2004-163 - Rev 00	Doxycycline hyclate	2011-06-01	Withdrawn by Holder	Chemical	2016-06-27	272
29/11/2025	Hovione	Portugal	Hovione PharmaScience Limited Taipa MO	CEP 1996-066 - Rev 07	Doxycycline hyclate	2024-07-18	Valid	Chemical		272

DOXY 200

DOXY 200

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

47 API Suppliers

21 USDMF

11 CEP/COS

1 JDMF

2 EU WC

2 KDMF

14 NDC API

1 VMF

21 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

47 Drugs in Development

FINISHED DOSAGE FORMULATIONS

239 FDF Dossiers

188 FDA Orange Book

11 Europe

15 Canada

25 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE

TABLET;ORAL - EQ 75MG BASE

TABLET;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE

CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE

SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI

3 Rochem International Inc

18 SPI Pharma

12 DKSH

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Pfanstiehl

6 Kirsch Pharma

4 ACG Worldwide

12 Actylis

2 Aeon Procare

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

33 BASF

1 CD Formulation

1 Clariant

11 Corel Pharma Chem

7 DFE Pharma

1 Esteem Industries

3 Finar

12 Gangwal Chemicals

6 Ideal Cures

5 Ingredion Pharma Solutions

27 Kerry

4 Keval Exports

5 Kima Chemical

6 Lonza Capsugel

22 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

4 Novo Excipients

4 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

CAPSULE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons